Vigil Neuroscience Net Invested Capital Over Time
| VIGL Stock | USD 3.19 0.19 6.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vigil Neuroscience Performance and Vigil Neuroscience Correlation. Vigil |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Invested Capital Analysis
Compare Vigil Neuroscience and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Net Invested Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLN | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 91.7 M | 54.1 M | 107.2 M | 107.3 M | 235.2 M | 176.4 M | 139.6 M |
| PMVP | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (70.5 M) | 359.1 M | 308.6 M | 246 M | 225.7 M | 187.5 M |
| GLUE | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (48.7 M) | 347.5 M | 271.4 M | 179.2 M | 162.4 M |
| TRDA | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (41.5 M) | 298.7 M | 212.6 M | 242.4 M | 153.3 M |
| THRD | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (46.7 M) | 289.1 M | 269.1 M | 135.6 M |
| CGEM | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (40.8 M) | (77.6 M) | 425 M | 535.2 M | 453.7 M | 233.7 M |
| EWTX | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (33.4 M) | 274.4 M | 346.7 M | 318.8 M | 195.7 M |
| RLYB | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (46 M) | 175.6 M | 169.3 M | 106.2 M | 84.7 M |
| PEPG | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (32.1 M) | 179.6 M | 108.4 M | 68.6 M |
| TYRA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (13.6 M) | 301.7 M | 257.8 M | 204.3 M | 164 M |
| CMPX | (70 M) | (70 M) | (70 M) | (70 M) | (70 M) | (70 M) | (70 M) | (70 M) | (70 M) | (103.7 M) | 49.3 M | 140.1 M | 181.6 M | 148.5 M | 156 M |
| PRTC | 221.8 M | 221.8 M | 221.8 M | 221.8 M | 221.8 M | 221.8 M | 221.8 M | 221.8 M | 287.5 M | 669.5 M | 711 M | 612.5 M | 560 M | 467.8 M | 554.7 M |
| OPT | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 38.2 M | 31.1 M | 64.8 M | 135.3 M | 48 M | (5.8 M) | 65.7 M | 43.2 M |
| PHVS | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 5 M | 18.7 M | 95.8 M | 205 M | 149.3 M | 384 M | 403.3 M |
Vigil Neuroscience and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Net Invested Capital description
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.My Equities
My Current Equities and Potential Positions
| Vigil Neuroscience | VIGL |
| Classification | Pharmaceutical Products |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.19
Check out Vigil Neuroscience Performance and Vigil Neuroscience Correlation. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Vigil Neuroscience technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.